{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:03:34Z","timestamp":1792893814301,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-005"],"award-info":[{"award-number":["2022-PUMCH-C-005"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,10]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The traditional neoadjuvant chemoradiotherapy (nCRT) combined with total mesorectal excision has been widely accepted as the standard treatment for patients with locally advanced rectal cancer (LARC). New strategies such as total neoadjuvant therapy (TNT) and neoadjuvant immunotherapy have shown great promise in certain patient populations. Currently, there is an urgent need to stratify patients before treatment to adopt the appropriate neoadjuvant strategies. Our previous study has shown that circulating tumour DNA (ctDNA) effectively reflects tumour burden and genetic characteristics and has significant predictive value for tumour recurrence, demonstrating great potential in guiding the choice of neoadjuvant strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The CINTS-R trial is a multicentre, open-label, randomised controlled trial designed to evaluate the efficacy and safety of a ctDNA-guided neoadjuvant treatment strategy compared with conventional neoadjuvant therapy regime in patients with LARC. The trial will enrol 470 patients diagnosed with LARC (staged cT3-4N0 or cTanyN1-2) with tumours located \u226412\u2009cm from the anal verge across seven centres in China. Patients will be randomly assigned in a 2:1 ratio to the experimental group or the control group. Patients in the experimental group will receive different intensities of neoadjuvant chemoradiotherapy (TNT or modified nCRT) or neoadjuvant immunotherapy based on the molecular features of the tumour, baseline ctDNA concentration and changes in ctDNA status early in treatment. Patients in the control group will receive modified nCRT. The primary endpoint is the 2-year disease-related treatment failure rate. The secondary endpoints include time to recurrence, 2-year overall survival, 2-year disease-free survival, clinical complete response (cCR) rate, near cCR rate and pathologically complete response rate, pathological tumour regression grade and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This protocol has been approved by the ethics committee of Peking Union Medical College Hospital, with approval number I-23PJ157, and by the institutional review boards of all the participating centres. All data will be collected and stored in a specially designed database. The results of our trial will be disseminated through peer-reviewed publications and presented at national and international academic conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      This trial is registered on ClinicalTrials.gov and the registration ID is\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05601505\">NCT05601505<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090765","type":"journal-article","created":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T20:50:36Z","timestamp":1738529436000},"page":"e090765","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Rationale and design of a multicentre randomised controlled trial on circulating tumour DNA-guided neoadjuvant treatment strategy for locally advanced rectal cancer (CINTS-R)"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05601505","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03042000","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05601505","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2020-5161","authenticated-orcid":false,"given":"Jiaolin","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9244-9344","authenticated-orcid":false,"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking University Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoju","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-7891","authenticated-orcid":false,"given":"Wei","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking University Third Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Chao-Yang Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huadan","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Radiology, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0799-8630","authenticated-orcid":false,"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College School of Basic Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"An","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Qiu","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guole","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,2]]},"reference":[{"key":"2025121601574092000_15.1.e090765.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2025121601574092000_15.1.e090765.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60484-0"},{"key":"2025121601574092000_15.1.e090765.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040694"},{"key":"2025121601574092000_15.1.e090765.4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/codi.13081","article-title":"Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review","volume":"17","author":"Ryan","year":"2015","journal-title":"Colorectal Dis"},{"key":"2025121601574092000_15.1.e090765.5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092567","article-title":"Selecting a TNT Schedule in Locally Advanced Rectal Cancer: Can We Predict Who Actually Benefits?","volume":"15","author":"Aschele","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025121601574092000_15.1.e090765.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00079-6"},{"key":"2025121601574092000_15.1.e090765.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30555-6"},{"key":"2025121601574092000_15.1.e090765.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x"},{"key":"2025121601574092000_15.1.e090765.9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121601574092000_15.1.e090765.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8"},{"key":"2025121601574092000_15.1.e090765.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445"},{"key":"2025121601574092000_15.1.e090765.12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"2025121601574092000_15.1.e090765.13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025121601574092000_15.1.e090765.14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051473","article-title":"Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation","volume":"15","author":"Udagawa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025121601574092000_15.1.e090765.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075"},{"key":"2025121601574092000_15.1.e090765.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2299"},{"key":"2025121601574092000_15.1.e090765.17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315852"},{"key":"2025121601574092000_15.1.e090765.18","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030427","article-title":"Evaluation of ctDNA in the Prediction of Response to Neoadjuvant Therapy and Prognosis in Locally Advanced Rectal Cancer Patients: A Prospective Study","volume":"16","author":"Morais","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025121601574092000_15.1.e090765.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00032"},{"key":"2025121601574092000_15.1.e090765.20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41571-021-00538-5","article-title":"International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer","volume":"18","author":"Fokas","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025121601574092000_15.1.e090765.21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1057947","article-title":"Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer","volume":"13","author":"Gao","year":"2023","journal-title":"Front Oncol"},{"key":"2025121601574092000_15.1.e090765.22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.30097","article-title":"Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis","volume":"3","author":"Kasi","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025121601574092000_15.1.e090765.23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijrobp.2017.05.048","article-title":"Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis","volume":"99","author":"Markovina","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:57:50Z","timestamp":1765879070000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,2]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjopen-2024-090765"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090765","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}